Gonzales C A, Bacchetti P, Khalili M
Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
J Viral Hepat. 2016 Mar;23(3):232-9. doi: 10.1111/jvh.12487. Epub 2015 Nov 10.
Hepatitis C infection (HCV) and menopause are associated with insulin resistance (IR), and IR accelerates HCV-induced liver disease. The relationship between menopause and IR has not been studied in this population. This study aimed to assess the impact of menopause on IR and metabolic syndrome in HCV. One hundred and three (69 men, 16 premenopausal, 18 postmenopausal women) noncirrhotic, nondiabetic HCV-infected adults underwent IR measurement via steady-state plasma glucose during a 240-min insulin suppression test. Metabolic syndrome was defined by at least three of five standard laboratory/clinical criteria. The patient characteristics were as follows: mean age 48 years, waist circumference 94.4 ± 12.4 cm and 37.9% Caucasian. SSPG was higher in postmenopausal than premenopausal women or men (mean difference 18, 95% CI -41 to 76 and 35, 95% CI -3 to 72 mg/dL; respectively). After adjusting for waist circumference, female gender, nonwhite race and triglycerides were positively associated and high-density lipoprotein negatively associated with steady-state plasma glucose. Compared to men, both pre- (Coef 48, 95% CI 12-84) and postmenopausal women (Coef 49, 95% CI 17-82) had higher steady-state plasma glucose. Compared to premenopausal women, men (OR 2.0, 95% CI 0.38-10.2) and postmenopausal women (OR 2.9, 95% CI 0.46-18.8) had higher odds of metabolic syndrome, but this was statistically nonsignificant. Both liver inflammation (OR 7.9) and nonwhite race (OR 6.9) were associated with metabolic syndrome. We conclude that women are at inc-reased risk for IR in HCV. There may also be an increased risk of metabolic syndrome postmenopause. Along with lifestyle modification and weight loss, women with metabolic abnormalities represent an especially at-risk group warranting HCV treatment to prevent adverse metabolic outcomes.
丙型肝炎病毒感染(HCV)与绝经均与胰岛素抵抗(IR)相关,且IR会加速HCV诱发的肝脏疾病。在这一人群中,绝经与IR之间的关系尚未得到研究。本研究旨在评估绝经对HCV患者IR及代谢综合征的影响。103名(69名男性、16名绝经前女性、18名绝经后女性)非肝硬化、非糖尿病的HCV感染成年人在240分钟胰岛素抑制试验期间通过稳态血糖测量IR。代谢综合征由五项标准实验室/临床标准中的至少三项来定义。患者特征如下:平均年龄48岁,腰围94.4±12.4厘米,37.9%为白种人。绝经后女性的稳态血糖高于绝经前女性或男性(平均差异分别为18,95%CI -41至76;35,95%CI -3至72毫克/分升)。在校正腰围后,女性性别、非白种人种族与甘油三酯与稳态血糖呈正相关,高密度脂蛋白与稳态血糖呈负相关。与男性相比,绝经前(系数48,95%CI 12 - 84)和绝经后女性(系数49,95%CI 17 - 82)的稳态血糖更高。与绝经前女性相比,男性(OR 2.0,95%CI 0.38 - 10.2)和绝经后女性(OR 2.9,95%CI 0.46 - 18.8)患代谢综合征的几率更高,但这在统计学上无显著意义。肝脏炎症(OR 7.9)和非白种人种族(OR 6.9)均与代谢综合征相关。我们得出结论,HCV女性患者发生IR的风险增加。绝经后发生代谢综合征的风险可能也会增加。除生活方式改变和减重外,有代谢异常的女性是特别高危的群体,需要进行HCV治疗以预防不良代谢结局。